Haploidentical HSCT: A 15-year experience at San Raffaele

C. Bonini, J. Peccatori, M. T L Stanghellini, L. Vago, A. Bondanza, N. Cieri, R. Greco, M. Bernardi, C. Corti, G. Oliveira, E. Zappone, C. Traversari, C. Bordignon, F. Ciceri

Research output: Contribution to journalArticlepeer-review


Hematopoietic SCT (HSCT) from HLA haploidentical family donors is a promising therapy for high-risk hematological malignancies. In the past 15 years at San Raffaele Scientific Institute, we investigated several transplant platforms and post transplant cellular-based interventions. We showed that T cell-depleted haploidentical transplantation followed by the infusion of genetically modified donor T cells (TK007 study, Eudract-2005-003587-34) promotes fast and wide immune reconstitution and GvHD control. This approach is currently tested in a phase III multicenter randomized trial (TK008 study, NCT00914628). We targeted patients with advanced leukeia with a sirolimus-based, calcineurin inhibitor-free prophylaxis of GvHD to allow the safe infusion of unmanipulated PBSCs from haploidentical family donors (TrRaMM study, Eudract 2007-5477-54). Results of these approaches are summarized and discussed.

Original languageEnglish
Pages (from-to)S67-S71
JournalBone Marrow Transplantation
Publication statusPublished - Jun 6 2015

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Haploidentical HSCT: A 15-year experience at San Raffaele'. Together they form a unique fingerprint.

Cite this